Drug General Information (ID: DDITVJC74I)
Drug Name			Human immunoglobulin G (intravenous)		Drug Info		Ravulizumab		Drug Info
Drug Type		Protein/peptide				Monoclonal antibody
Therapeutic Class		Immune Globulins				Selective Immunosuppressants

Mechanism of Human immunoglobulin G (intravenous)-Ravulizumab Interaction (Severity Level: Minor)
Attenuated pharmacological effects (Unspecific) Click to Show/Hide Mechanism Graph
Drug Name		Human immunoglobulin G (intravenous)				Ravulizumab
Mechanism		Reduce the therapeutic efficacy of ravulizumab				Ravulizumab
Key Mechanism Factor 1
		Factor Name		Pharmacodynamics
		Factor Description		Reduced pharmacological effects leading to insufficient efficacy and/or treatment failure.
Mechanism Description		Attenuated pharmacological effects of  Ravulizumab when combined with Human immunoglobulin G (intravenous)

References
1	Cerner Multum, Inc. "Australian Product Information.".
2	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
3	Product Information. Ultomiris (ravulizumab). Alexion Pharmaceuticals Inc, Cheshire, CT.